Department of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, P.R. China.
Department of Pathology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, 610041, Sichuan, China.
Diagn Pathol. 2024 Aug 15;19(1):110. doi: 10.1186/s13000-024-01534-w.
Compared to primary breast sarcoma (BSs), radiotherapy-induced sarcoma (RIS) is a less frequent type of secondary breast sarcoma. Undifferentiated pleomorphic sarcoma (UPS) is an even rarer occurrence within the RIS category. This study aimed to present the clinicopathologic and molecular features of breast radiotherapy-induced UPS.
A retrospective study was conducted at the Third Affiliated Hospital of Soochow University to analyze three patients with radiation-induced undifferentiated pleomorphic sarcoma (UPS) following breast cancer, spanning from 2006 to 2023. The clinical and pathological variables were extracted from the medical records, while immunohistochemistry was employed to analyze the immunophenotypes of these tumors. Genomic characteristics were assessed through DNA and RNA sequencing techniques. Another 15 cases from the literature were also reviewed to better characterize the tumor.
The affected areas encompass the chest wall and breasts, with an incubation period ranging from 6 to 17 years. The tumor cells exhibit pleomorphism and demonstrate a high degree of pathological mitosis. Notably, two cases displayed an accelerated disease progression, characterized by recurrent tumors and metastases occurring within short intervals of 48 and 7 months respectively subsequent to the initial diagnosis. The two prevailing identified genes were TP53 (2/3, 66.7%) and RB1 (1/3, 33.3%). Through analysis of somatic copy number variation (CNV), it was discovered that two oncogenes, MCL1 (1/3, 33.3%) and MYC (1/3, 33.3%), had experienced gains in CNV. The Tumor Mutational Burden (TMB) values for case 1, case 2, and case 3 were 5.9 mut/Mb, 1.0 mut/Mb, and 3.0 mut/Mb, respectively. Moreover, the analysis of RNA-NGS (next-generation sequencing) revealed the presence of a novel gene fusion, named COL3A1-GULP1, in case 2.
Based on our thorough analysis of research findings and previous reports, it is evident that radiotherapy-induced UPS exhibits a highly diverse and frequently severe clinical and biological behavior. Identifying tumor formation using genome sequencing can help understand its biological behavior and determine personalized treatments.
与原发性乳腺肉瘤(BSs)相比,放疗诱导的肉瘤(RIS)是一种较少见的继发性乳腺肉瘤。未分化多形性肉瘤(UPS)在 RIS 类别中更为罕见。本研究旨在介绍乳腺癌放疗诱导 UPS 的临床病理和分子特征。
在苏州大学附属第三医院进行了一项回顾性研究,分析了 2006 年至 2023 年期间三例乳腺癌放疗诱导的未分化多形性肉瘤(UPS)患者的临床和病理变量。从病历中提取,同时通过免疫组织化学分析这些肿瘤的免疫表型。通过 DNA 和 RNA 测序技术评估基因组特征。还回顾了来自文献的另外 15 例病例,以更好地描述肿瘤。
受影响的区域包括胸壁和乳房,潜伏期为 6 至 17 年。肿瘤细胞表现出多形性,并表现出高度的病理性有丝分裂。值得注意的是,有两例表现出加速的疾病进展,特征为复发性肿瘤和转移,分别在初始诊断后 48 个月和 7 个月内发生。两个主要鉴定的基因是 TP53(2/3,66.7%)和 RB1(1/3,33.3%)。通过分析体细胞拷贝数变异(CNV),发现两个癌基因 MCL1(1/3,33.3%)和 MYC(1/3,33.3%)经历了 CNV 的增益。病例 1、病例 2 和病例 3 的肿瘤突变负担(TMB)值分别为 5.9 mut/Mb、1.0 mut/Mb 和 3.0 mut/Mb。此外,RNA-NGS(下一代测序)分析显示病例 2 中存在一种新的基因融合,命名为 COL3A1-GULP1。
根据我们对研究结果和以往报告的全面分析,放疗诱导的 UPS 表现出高度多样化和频繁严重的临床和生物学行为。使用基因组测序识别肿瘤形成有助于了解其生物学行为并确定个性化治疗。